managing-contrast-reactions

# Managing Contrast Reactions

Guides contrast reaction grading, treatment, and premedication protocols for future studies.

## Why This Skill Exists

Adverse reactions to iodinated and gadolinium-based contrast media are the most common life-threatening emergencies in the radiology department. While severe reactions are rare (0.02–0.04% for iodinated contrast, even lower for gadolinium), they can be fatal if not recognized and treated within minutes. The ACR Manual on Contrast Media (updated annually) is the definitive reference for reaction classification, treatment algorithms, premedication protocols, and contrast safety screening. Every radiologist, technologist, and nurse working in an imaging department must be trained in contrast reaction recognition and treatment.

Regulatory requirements from CMS and The Joint Commission mandate that radiology departments maintain emergency equipment, medications, and trained personnel for contrast reaction management. ACR accreditation requires documented contrast reaction protocols and regular training drills. Failure to document adverse reactions prevents proper flagging of patient allergies and puts patients at risk for re-exposure. This skill provides the systematic framework for grading reactions, executing treatment, documenting events, and planning safe future imaging.

---

## Checkpoint A: Pre-Draft Intake (Mandatory)

1. **What contrast agent was administered?** (Default: Identify specific agent, dose, and route)
2. **What type of reaction occurred?** (Default: Classify as allergic-like, physiologic, or vasovagal)
3. **When did symptoms begin relative to injection?** (Default: Document onset time)
4. **What symptoms did the patient exhibit?** (Default: Document all signs and symptoms)
5. **What treatment was administered?** (Default: Document all interventions)
6. **What was the patient outcome?** (Default: Resolved, transferred, admitted)

### Documents to Request

- Contrast administration record (agent, dose, rate, route)
- Patient allergy history and prior contrast reaction documentation
- Vital signs at baseline and during/after reaction
- Medication administration record for treatment given
- Patient medical history (asthma, cardiac disease, beta-blocker use)
- ACR Manual on Contrast Media (current edition) — department copy

---

## Step 1: Classify the Reaction

### ACR Reaction Classification

| Severity | Allergic-Like (Anaphylactoid) | Physiologic (Chemotoxic) |
|----------|------------------------------|--------------------------|
| **Mild** | Limited urticaria/hives, pruritus, nasal congestion, sneezing, conjunctivitis, limited cutaneous edema | Nausea, vomiting, headache, mild flushing, chills, warmth/heat sensation, anxiety, altered taste |
| **Moderate** | Diffuse urticaria/hives, facial edema without dyspnea, throat tightness without stridor, mild bronchospasm/wheezing | Hypertensive urgency, vasovagal reaction (isolated bradycardia and hypotension) |
| **Severe** | Laryngeal edema with stridor, severe bronchospasm, anaphylaxis (hypotension + urticaria/angioedema), cardiac arrest | Seizures, arrhythmia, severe hypertension/hypotension, pulmonary edema |

### Timing Classification
| Timing | Definition | Common Presentation |
|--------|-----------|-------------------|
| Acute | Within 1 hour of injection | Most allergic-like and physiologic reactions |
| Delayed | 1 hour to 7 days post-injection | Skin rash, urticaria, joint pain, fever |
| Very late | >7 days | Thyroid dysfunction (iodinated), NSF (gadolinium — historical) |

---

## Step 2: Execute Treatment Protocol

### Mild Reactions

| Symptom | Treatment | Monitoring |
|---------|-----------|-----------|
| Limited urticaria | Diphenhydramine 25–50 mg PO or IV | Observe 30 min |
| Nausea/vomiting | Ondansetron 4 mg IV; position on side | Observe until resolved |
| Pruritus without hives | Diphenhydramine 25–50 mg PO or IV | Observe 30 min |
| Warmth/flushing | Reassurance; self-limiting | Brief observation |

### Moderate Reactions

| Symptom | Treatment | Monitoring |
|---------|-----------|-----------|
| Diffuse urticaria | Diphenhydramine 50 mg IV + consider epinephrine 0.3 mg IM | Continuous monitoring 60 min |
| Facial/laryngeal edema (no stridor) | Epinephrine 0.3 mg IM (1:1000); diphenhydramine 50 mg IV | Continuous monitoring; prepare for intubation |
| Bronchospasm (mild) | Albuterol MDI 2–4 puffs; epinephrine 0.3 mg IM if not responsive | Continuous pulse oximetry |
| Vasovagal (bradycardia + hypotension) | Elevate legs, IV NS bolus 500–1000 mL; atropine 0.6–1.0 mg IV if HR <60 and symptomatic | Continuous cardiac monitoring |
| Hypertensive urgency | Nitroglycerin 0.4 mg SL; labetalol 20 mg IV if severe | Blood pressure monitoring q5 min |

### Severe Reactions — Call Code/Rapid Response

| Symptom | Treatment | Next Steps |
|---------|-----------|-----------|
| Anaphylaxis | **Epinephrine 0.3 mg IM (thigh)** — repeat q5–15 min; IV access; NS wide open; call code team | Transfer to ED/ICU |
| Laryngeal edema with stridor | Epinephrine 0.3 mg IM; racemic epinephrine neb; prepare for emergent intubation | Anesthesia/airway team STAT |
| Severe bronchospasm | Epinephrine 0.3 mg IM; continuous albuterol neb; consider IV epinephrine infusion | ICU transfer |
| Cardiac arrest | ACLS protocol; epinephrine 1 mg IV (1:10,000) q3–5 min; CPR; defibrillation if shockable rhythm | Full resuscitation |
| Seizure | Protect airway; lorazepam 2–4 mg IV; oxygen | Neurology consult |

**Critical points:**
- Epinephrine IM (1:1000, 0.3 mg) is the first-line treatment for anaphylaxis — do not delay
- Beta-blocker patients may require glucagon 1–5 mg IV if epinephrine is ineffective
- IV epinephrine (1:10,000) is reserved for cardiac arrest or refractory anaphylaxis with IV access

---

## Step 3: Document the Reaction

### Required Documentation Elements

| Element | Detail |
|---------|--------|
| Contrast agent | Name, concentration, volume, rate, route |
| Reaction onset | Time after injection |
| Symptoms | All signs and symptoms in chronological order |
| Severity | Mild, moderate, or severe per ACR classification |
| Type | Allergic-like, physiologic, or vasovagal |
| Treatment | All medications with dose, route, and time administered |
| Response to treatment | Symptom resolution timeline |
| Outcome | Resolved and discharged, transferred to ED, admitted |
| Provider | Name and credentials of treating physician |
| EMR allergy flag | Updated to reflect contrast allergy with reaction details |

### Documentation Template
```
CONTRAST REACTION REPORT
Agent: [name] [concentration] [volume] [route]
Time of injection: [HH:MM]
Reaction onset: [HH:MM] ([X] minutes post-injection)
Symptoms: [list all symptoms chronologically]
Severity: [Mild/Moderate/Severe] [Allergic-like/Physiologic]
Treatment: [medication, dose, route, time] for each intervention
Response: [symptoms resolved at HH:MM / transferred / admitted]
Provider: Dr. [Name]
EMR allergy flag updated: Yes/No
Patient education provided: Yes/No
Premedication plan documented for future studies: Yes/No
```

---

## Step 4: Plan for Future Studies

### Premedication Protocols

| Protocol | Schedule | Medications |
|----------|----------|------------|
| **Standard (13-hour)** | 13h, 7h, 1h before contrast | Prednisone 50 mg PO at each interval + diphenhydramine 50 mg PO/IM/IV 1h before |
| **Accelerated (5-hour)** | 5h, 1h before contrast | Methylprednisolone 40 mg IV at each interval + diphenhydramine 50 mg IV 1h before |
| **Emergency (<5 hours)** | ASAP and at contrast time | Methylprednisolone 40 mg IV ASAP + diphenhydramine 50 mg IV 1h before (reduced efficacy) |

### Decision Matrix for Future Contrast Studies

| Prior Reaction | Same Class Contrast | Different Class | Alternative Modality |
|---------------|--------------------|-----------------|--------------------|
| Mild allergic-like | Premedicate + switch to different agent | Premedicate | Preferred if clinically equivalent |
| Moderate allergic-like | Premedicate + switch agent; consider alternative modality | Premedicate + switch agent | Strongly preferred |
| Severe allergic-like (anaphylaxis) | Avoid same class; strong risk-benefit discussion | Premedicate + different agent if essential | Strongly recommended |
| Physiologic (nausea, warmth) | Reduce injection rate; no premedication needed | N/A | Not necessary |
| Vasovagal | Pre-hydrate; slow injection; no premedication needed | N/A | Not necessary |

---

## Step 5: Department Preparedness Requirements

### Emergency Equipment Checklist

| Item | Location | Check Frequency |
|------|----------|----------------|
| Epinephrine 1:1000 (IM) auto-injectors or ampules | Each scanner room | Daily |
| Diphenhydramine 50 mg injectable | Each scanner room | Daily |
| Albuterol MDI or nebulizer | Contrast injection area | Daily |
| Atropine 1 mg injectable | Code cart | Per institutional policy |
| IV supplies (catheters, NS bags, tubing) | Each scanner room | Daily |
| Oxygen delivery (nasal cannula, non-rebreather, BVM) | Each scanner room | Daily |
| Pulse oximeter and BP monitor | Each scanner room | Daily |
| Code cart/defibrillator | Accessible within 2 minutes | Per institutional policy |

---

## Checkpoint B: Post-Draft Alignment (Mandatory)

1. Is the reaction correctly classified by severity and type (ACR framework)?
2. Was treatment appropriate for the reaction severity?
3. Is the EMR allergy flag updated with reaction details?
4. Is a premedication plan documented for future contrast studies?
5. Is the reaction report complete with all required elements?

---

## Quality Audit

- [ ] Contrast agent, dose, and route are documented
- [ ] Reaction onset time is recorded relative to injection
- [ ] Symptoms are listed chronologically
- [ ] Severity is classified per ACR Manual on Contrast Media
- [ ] Type is classified (allergic-like vs. physiologic vs. vasovagal)
- [ ] Treatment medications include dose, route, and administration time
- [ ] Outcome is documented (resolved, transferred, admitted)
- [ ] EMR allergy flag is updated with specific contrast agent and reaction details
- [ ] Premedication protocol is specified for future studies
- [ ] Patient education was provided regarding the reaction and future risks
- [ ] Institutional adverse event reporting system is notified
- [ ] Emergency equipment checklist is current for the scanner room
- [ ] Staff contrast reaction training is documented and current

---

## Guidelines

1. Epinephrine IM is the first-line treatment for anaphylaxis — every second of delay worsens outcomes; do not substitute with diphenhydramine or steroids as first-line.
2. Always update the EMR allergy flag with the specific contrast agent, reaction type, and severity — vague flags like "contrast allergy" are insufficient.
3. Premedication reduces but does not eliminate the risk of repeat reactions — document the residual risk in the informed consent discussion.
4. Physiologic reactions (nausea, warmth, metallic taste) do not require premedication for future studies; document as "physiologic" in the allergy history to avoid unnecessary premedication.
5. Patients on beta-blockers may have refractory anaphylaxis — have glucagon available and flag these patients during pre-screening.
6. The 13-hour premedication protocol has the strongest evidence; the accelerated and emergency protocols have reduced efficacy and should be used only when the study cannot wait.
7. Report all moderate and severe reactions through the institutional adverse event reporting system; mild reactions should be documented in the medical record at minimum.